Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment

Autor: Kazuhiko Yonezawa, Hiroyuki Kaneto, Hirofumi Akashi, Noriyuki Akutsu, Takehiro Hirano, Yasunao Numata, Satoshi Yamaoka, Shigeru Sasaki, Katsunori Tanaka, Toshihiro Ban, Seiya Nakahara, Hideyasu Takagi, Takeshi Matsui, Keisuke Ishigami, Takeya Adachi, Kohei Nakachi, Itaru Yamamoto, Hiroyuki Isshiki, Kohei Wagatsuma, Atsushi Yawata, Hiroshi Nakase, Masayuki Tsujisaki
Rok vydání: 2021
Předmět:
Cyclopropanes
medicine.medical_specialty
Aminoisobutyric Acids
Pyrrolidines
Cirrhosis
Every Two Weeks
Genotype
Proline
Lactams
Macrocyclic
Low density lipoprotein cholesterol
Hepacivirus
030204 cardiovascular system & hematology
Antiviral Agents
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
High-density lipoprotein
Leucine
Quinoxalines
Internal medicine
Internal Medicine
medicine
Clinical endpoint
chronic hepatitis C
Humans
Sulfonamides
Triglyceride
business.industry
Cholesterol
Cholesterol
HDL
cholesterol
Cholesterol
LDL
General Medicine
Hepatitis C
Chronic
medicine.disease
chemistry
interferon-free direct-acting antiviral treatment
Original Article
Benzimidazoles
lipids (amino acids
peptides
and proteins)
030211 gastroenterology & hepatology
Glecaprevir / pibrentasvir
business
Zdroj: Internal Medicine
ISSN: 1349-7235
0918-2918
DOI: 10.2169/internalmedicine.7098-21
Popis: Objective The change in serum lipid levels by direct-acting antiviral (DAA) treatment for chronic hepatitis C varies depending on the type of DAA. How the lipid level changes induced by glecaprevir-pibrentasvir (G/P) treatment contribute to the clinical outcome remains unclear. We conducted a prospective observational study to evaluate the effectiveness of G/P treatment and the lipid level changes. Methods The primary endpoint was a sustained virologic response at 12 weeks (SVR12). The total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels and LDL-C/HDL-C (L/H) ratio were measured every two weeks. Patients This study included 101 patients. Seventeen cases of liver cirrhosis and nine cases of DAA retreatment were registered. The G/P treatment period was 8 weeks in 74 cases and 12 weeks in 27 cases. Results SVR12 was evaluated in 96 patients. The rate of achievement of SVR12 in the evaluable cases was 100%. We found significantly elevated TC and LDL-C levels over the observation period compared to baseline. The serum levels of HDL-C did not change during treatment but were significantly increased after treatment compared to baseline. The L/H ratio was significantly increased two weeks after the start of treatment but returned to the baseline after treatment. Conclusion The primary endpoint of the SVR12 achievement rate was 100%. G/P treatment changed the serum lipid levels. Specifically, the TC and LDL-C levels increased during and after treatment, and the HDL-C levels increased after treatment. G/P treatment may be associated with a reduced thrombotic risk. Therefore, validation in large trials is recommended.
Databáze: OpenAIRE
Externí odkaz: